ArticleDigestive diseases and sciences2026
Low Fecal Elastase-1: A Non-negligible Factor in Functional Dyspepsia Patients.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Intervention WithFood science & nutrition · 2026Article
- Investigation of the putative mechanism by whichFrontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
BACKGROUND AND
aimFunctional dyspepsia (FD) is one of the most prevalent functional gastrointestinal disorders. The occurrence of dyspepsia has been reported to be associated with a deficiency or dysfunction of digestive enzymes. Although the pancreas plays a critical role in secreting digestive enzymes, the relationship between FD and pancreatic exocrine insufficiency (PEI) remains unclear. This study aims to evaluate the prevalence of low Fecal elastase-1 (FE-1) level, a recognized indicator of PEI, in FD patients and explore potential risk factors contributing to this condition.
methodsThis cross-sectional study enrolled 76 FD patients. The FE-1 level was measured using a commercial ELISA kit. An FE-1 level below 200 μg/g stool was defined as abnormal. Clinical characteristics and gut microbiota composition were compared between FD patients with low FE-1 level (FE-L) and those with normal FE-1 level (FE-N). Logistic regression analysis was used to identify independent risk factors for low FE-1 level in FD patients.
resultsThe prevalence of low FE-1 level among FD patients was 19.7%. Compared to the FE-N group, the FE-L group exhibited higher gastrointestinal symptoms scores, anxiety scores and lower quality of life scores (P < 0.05). Logistic regression analysis revealed that male gender and anxiety state were independent risk factors for low FE-1 level. Gut microbiota analysis demonstrated that Prevotella were significantly enriched, while Bacteroides and Bifidobacterium were decreased in the FE-L group (LDA > 3, P < 0.05).
conclusionsThe present study suggests that a subset of patients with FD have FE-1 secretion insufficiency and might benefit from pancreatic enzyme supplementation therapy.
Indexed as
Identifiers
41152608What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.